Marapharm Ventures Inc. (CSE: MDM) (OTXQX: MRPHF) (FSE: 2M0) (“Marapharm” or the “Company”), announced in a news release published on February 14, 2018, the closing of “420 Express Delivery, Inc,” dba “Green Leaf Wellness,” a dispensary located in the City of Desert Hot Springs, California.
We are delighted to report that the transition of business has been remarkably smooth and well received by existing staff, patrons, and clients.
Based on current performance, the dispensary in on track to double sales in the first month of operations.
Our legal counsellor, Director of Operations, two consultants and staff, have been instrumental in the success of the transition of “Green Leaf Wellness.” Audits and reviews of inventory, accounting, staffing, security, vendors, and compliance have been the focus of the transition, which will continue to be refined to ensure the success of Green Leaf Wellness.
“The team’s efforts have exceeded our expectations! To all of those involved, thank you for your commitment to making this a great beginning of our venture ahead”. Linda Sampson, CEO
ABOUT MARAPHARM VENTURES INC.
Marapharm is a publicly traded company investing in the medical and recreational cannabis space, since 2014. Marapharm has rapidly expanded to include having cultivation, production and dispensary locations in the key North American states of Washington, Nevada, and California, and are seeking expansion opportunities worldwide.
FOR FURTHER INFORMATION:
www.marapharm.com or Linda Sampson, CEO 778-583-4476 email firstname.lastname@example.org
Twitter: twitter.com/marapharm Web
Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, and in Europe, ticker symbol 2Mo on the FSE. Marapharm also trades on other recognized platforms in Europe including Stuttgart, Tradegate, L & S, Quotnx, Dusseldorf, Munich, and Berlin.
Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.
MARIJUANA INDUSTRY INVOLVEMENT:
Canadian listings (CSE) will remain in good standing as long as they provide the disclosure that is rightly required by regulators and complying with applicable licensing requirements and the regulatory framework enacted by the applicable state in which they operate.
Marapharm owns marijuana licenses in California and Nevada. Marijuana is legal in each state however marijuana remains illegal under US federal law and the approach to enforcement of US federal law against marijuana is subject to change. Shareholders and investors need to be aware that adverse enforcement actions could affect their investments and that Marapharm’s ability to access private and public capital could be affected and or could not be available to support continuing operations. Marapharm’s business is conducted in a manner consistent with state law and is in compliance with licensing requirements.
Copies of licenses are posted on Marapharm’s website. Marapharm has internal compliance procedures in place and has compliance focused attorneys engaged in jurisdictions to monitor changes in laws for compliance with US federal and state law on an ongoing basis. These law firms inform any necessary changes to our policies and procedures for compliance in Canada and the US.
FORWARD – LOOKING STATEMENTS:
Certain statements contained in this news release constitute forward looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, ‘may”, “will”, “project”, “should”, ‘believe”, and similar expressions are intended to identify forward- looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward- looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.